- Home
- TAIT vs NXTC Comparison
TAIT vs NXTC Comparison
Compare TAIT & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAIT
- NXTC
- Stock Information
- Founded
- TAIT 1989
- NXTC 2015
- Country
- TAIT United States
- NXTC United States
- Employees
- TAIT N/A
- NXTC N/A
- Industry
- TAIT Electronic Components
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- TAIT Technology
- NXTC Health Care
- Exchange
- TAIT Nasdaq
- NXTC Nasdaq
- Market Cap
- TAIT 13.3M
- NXTC 13.9M
- IPO Year
- TAIT 1995
- NXTC 2019
- Fundamental
- Price
- TAIT $2.18
- NXTC $0.48
- Analyst Decision
- TAIT
- NXTC Strong Buy
- Analyst Count
- TAIT 0
- NXTC 2
- Target Price
- TAIT N/A
- NXTC $3.50
- AVG Volume (30 Days)
- TAIT 16.6K
- NXTC 336.1K
- Earning Date
- TAIT 08-13-2025
- NXTC 07-31-2025
- Dividend Yield
- TAIT 9.21%
- NXTC N/A
- EPS Growth
- TAIT N/A
- NXTC N/A
- EPS
- TAIT 0.01
- NXTC N/A
- Revenue
- TAIT $4,260,000.00
- NXTC N/A
- Revenue This Year
- TAIT N/A
- NXTC N/A
- Revenue Next Year
- TAIT N/A
- NXTC N/A
- P/E Ratio
- TAIT $225.79
- NXTC N/A
- Revenue Growth
- TAIT N/A
- NXTC N/A
- 52 Week Low
- TAIT $2.01
- NXTC $0.22
- 52 Week High
- TAIT $3.05
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- TAIT 47.75
- NXTC 44.82
- Support Level
- TAIT $2.15
- NXTC $0.45
- Resistance Level
- TAIT $2.28
- NXTC $0.51
- Average True Range (ATR)
- TAIT 0.07
- NXTC 0.07
- MACD
- TAIT 0.00
- NXTC -0.01
- Stochastic Oscillator
- TAIT 28.00
- NXTC 3.24
About TAIT Taitron Components Incorporated
Taitron Components Inc is a supplier of originally designed and manufactured (ODM) products that include value-added engineering and turn-key solutions. It focuses on providing original equipment manufacturers (OEMs) and contracts electronic manufacturers (CEMs) with ODM products for their multi-year turn-key projects and ODM electronic components. The company's product offerings range from discrete semiconductors to small electronic devices. The company also distributes brand-name electronic components with a vast inventory available on hand. Its Taiwan and China locations, provide support for inventory sourcing, purchases, and coordinating the manufacture of ODM Projects and ODM Components.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.